Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Current Assets (2017 - 2025)

Inmune Bio's Current Assets history spans 9 years, with the latest figure at $30.7 million for Q3 2025.

  • For Q3 2025, Current Assets fell 14.45% year-over-year to $30.7 million; the TTM value through Sep 2025 reached $30.7 million, down 14.45%, while the annual FY2024 figure was $22.7 million, 43.26% down from the prior year.
  • Current Assets for Q3 2025 was $30.7 million at Inmune Bio, down from $36.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $90.9 million in Q3 2021 and bottomed at $21.0 million in Q1 2025.
  • The 5-year median for Current Assets is $45.6 million (2023), against an average of $50.1 million.
  • The largest annual shift saw Current Assets skyrocketed 604.93% in 2021 before it crashed 47.57% in 2024.
  • A 5-year view of Current Assets shows it stood at $82.6 million in 2021, then dropped by 21.71% to $64.7 million in 2022, then tumbled by 38.24% to $39.9 million in 2023, then tumbled by 43.26% to $22.7 million in 2024, then soared by 35.34% to $30.7 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Current Assets are $30.7 million (Q3 2025), $36.0 million (Q2 2025), and $21.0 million (Q1 2025).